Skip to main content
Premium Trial:

Request an Annual Quote

Affibody to Develop, Produce Protein Ligands for Agilent s Sample Prep Products

NEW YORK, Aug. 23 (GenomeWeb News) - Affibody of Stockholm, Sweden, will develop protein affinity ligands for Agilent Technologies' protein sample preparation products, the companies said today.

 

Under the agreement, Affibody will design and develop affinity capture ligands for certain proteins specified by Agilent, using its Affibody technology. Agilent plans to incorporate these reagents into its protein removal technology for sample preparation. Eventually, Affibody will supply Agilent with production quantities of the reagents.

 

Affibody molecules are highly specific affinity proteins that mimic monoclonal antibodies. They are produced by combinatorial protein engineering applied on a proprietary scaffold.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.